临床误诊误治2024,Vol.37Issue(13) :77-81.DOI:10.3969/j.issn.1002-3429.2024.13.016

丙戊酸镁联合多奈哌齐治疗对阿尔茨海默病精神行为状态、血清神经递质和细胞因子的影响

Effect of Magnesium Valproate Combined with Donepezil on Mental and Behavioral State,Serum Neurotransmitters and Cytokines in Patients with Alzheimer's Disease

乔育 张阳 雷彪 于蓬勃 王晓峰 杨晓亮
临床误诊误治2024,Vol.37Issue(13) :77-81.DOI:10.3969/j.issn.1002-3429.2024.13.016

丙戊酸镁联合多奈哌齐治疗对阿尔茨海默病精神行为状态、血清神经递质和细胞因子的影响

Effect of Magnesium Valproate Combined with Donepezil on Mental and Behavioral State,Serum Neurotransmitters and Cytokines in Patients with Alzheimer's Disease

乔育 1张阳 2雷彪 1于蓬勃 1王晓峰 1杨晓亮3
扫码查看

作者信息

  • 1. 721000 陕西宝鸡,宝鸡市中医医院神经外科
  • 2. 721000 陕西宝鸡,宝鸡市中医医院精神科
  • 3. 721004 陕西宝鸡,解放军九八七医院神经外科
  • 折叠

摘要

目的 探究丙戊酸镁联合多奈哌齐对阿尔茨海默病患者血清脂蛋白磷脂酶A2(Lp-PLA2)、铜蓝蛋白(CER)、脑源性神经营养因子(BDNF)水平及精神行为状态的影响.方法 选择104 例2020 年8 月至2023 年8 月就诊的阿尔茨海默病患者,以随机数字表法分为联合组、单药组,各52 例.单药组接受盐酸多奈哌齐片治疗,联合组在单药组基础上接受丙戊酸镁片治疗,2 组均治疗16 周.观察 2 组治疗前、治疗 16 周后的精神行为状态评分、血清神经递质和细胞因子水平,以及治疗期间不良反应发生情况.结果 治疗16 周后,联合组和单药组简明蒙特利尔认知评估量表评分及血清γ-氨基丁酸、谷氨酸、5-羟色胺、CER、BDNF水平高于治疗前,且联合组高于单药组(P<0.05).治疗16 周后,联合组和单药组阿尔茨海默病评定量表-认知量表、Blessed-Roth行为量表、神经精神症状问卷评分及血清Lp-PLA2 水平低于治疗前,且联合组低于单药组(P<0.05).治疗期间,联合组、单药组不良反应总发生率分别为21.15%(11/52)、23.08%(12/52),组间比较无统计学差异(P>0.05).结论 丙戊酸镁联合多奈哌齐可有效提高阿尔茨海默病患者血清CER、BDNF及神经递质水平,降低血清Lp-PLA2 水平,进而减轻神经细胞损伤,促进神经元信息的传递,有效改善其精神行为状态,且安全性良好.

Abstract

Objective To explore the effects of Magnesium Valproate combined with Donepezil on serum lipoprotein phospholipase A2(Lp-PLA2),ceruloplasmin(CER)and brain-derived neurotrophic factor(BDNF)levels and mental and behavioral state of patients with Alzheimer's disease.Methods A total of 104 patients with Alzheimer's disease treated from August 2020 to August 2023 were randomly divided into combination group(n=52)and monotherapy group(n=52).The monotherapy group was treated with Donepezil Hydrochloride tablets,and the combination group was treated with Magnesium Valproate tablets on the basis of monotherapy group.Both groups were treated for 16 weeks.The scores of mental and behav-ioral status,the levels of serum neurotransmitters and cytokines,and the occurrence of adverse reactions during treatment were observed before and at 16 weeks after treatment.Results At 16 weeks after treatment,the scores of abbreviated Montreal Cognitive Assessment Scale and serum levels of γ-aminobutyric acid,glutamic acid,5-hydroxytryptamine,CER and BDNF in combination group and monotherapy group were higher than those before treatment,and higher in the combination group than in the monotherapy group(P<0.05).At 16 weeks after treatment,the scores of Alzheimer's disease Assessment Scale-Cogni-tive Subscale,Blessed Roth Behavioral Scale,Neuropsychiatric symptom questionnaire and serum Lp-PLA2 levels in combina-tion group and monotherapy group were lower than those before treatment,and lower in the combination group than in the monotherapy group(P<0.05).During treatment,the total incidence of adverse reactions in combination group and mono-therapy group was 21.15%(11/52)and 23.08%(12/52),respectively,and there was no significant difference between the two groups(P>0.05).Conclusion Magnesium Valproate combined with Donepezil could effectively improve the levels of serum CER,BDNF and neurotransmitter in patients with Alzheimer's disease,and reduce the level of serum Lp-PLA2,thereby reducing the injury of nerve cells,promoting the transmission of neuronal information,and effectively improving their mental and behavioral state with good safety.

关键词

阿尔茨海默病/丙戊酸镁/多奈哌齐/认知/脂蛋白磷脂酶A2/铜蓝蛋白/脑源性神经营养因子/γ-氨基丁酸

Key words

Alzheimer's disease/Magnesium valproate/Donepezil/Cognition/Lipoprotein phospholipase A2/Ceru-loplasmin/Brain-derived neurotrophic factor/γ-aminobutyric acid

引用本文复制引用

基金项目

陕西省自然科学基础研究计划项目(2024JC-YBMS-734)

出版年

2024
临床误诊误治
解放军白求恩国际和平医院

临床误诊误治

CSTPCD
影响因子:0.914
ISSN:1002-3429
参考文献量19
段落导航相关论文